Data Management And Sharing System of China National Clinical Research Center for Neurological Diseases
Safety and efficacy of intravenous recombinant human prourokinase for acute ischaemic stroke within 4·5 h after stroke onset (PROST-2): a phase 3, open-label, non-inferiority, randomised controlled trial
First author：Shuya Li
Corresponding author：Yongjun Wang
essential_information
2024-11-11
Published articles
Journal：Lancet Neurology
Publication type: Article
IF(IF): 46.5
PMID: 39617030 Link To Pubmed Full text Download
Background And Purpose
Intra-arterial prourokinase has been shown to be a promising thrombolytic agent in patients with acute ischaemic stroke
Method
Log-binomial regression